NUT midline carcinoma (NMC) is an aggressive type of squamous cell carcinoma that is defined by the presence of BRD-NUT fusion oncogenes, which encode chimeric proteins that block differentiation and maintain tumor growth. BRD-NUT oncoproteins contain two bromodomains whose binding to acetylated histones is required for the blockade of differentiation in NMC, but the mechanisms by which BRD-NUT act remain uncertain. Here, we provide evidence that MYC is a key downstream target of BRD4-NUT. Expression profiling of NMCs shows that the set of genes whose expression is maintained by BRD4-NUT is highly enriched for MYC upregulated genes, and MYC and BRD4-NUT protein expression is strongly correlated in primary NMCs. More directly, we find that BRD4-NUT associates with the MYC promoter and is required to maintain MYC expression in NMC cell lines. Moreover, both siRNA knockdown of MYC and a dominant-negative form of MYC, omomyc, induce differentiation of NMC cells. Conversely, differentiation of NMC cells induced by knockdown of BRD4-NUT is abrogated by enforced expression of MYC. Together, these findings suggest that MYC is a downstream target of BRD4-NUT that is required for maintenance of NMC cells in an undifferentiated, proliferative state. Our findings support a model in which dysregulation of MYC by BRD-NUT fusion proteins has a central role in the pathogenesis of NMC.
INTRODUCTION
NUT midline carcinoma (NMC) is a genetically distinct subtype of squamous cancer that occurs in both children and adults of all ages. NMC is extremely aggressive, having a median survival of 6.7 months, 1 and responds poorly to standard chemotherapeutic strategies. NMC is a rare, but particularly valuable model through which to study squamous carcinoma because it is a genetically simple tumor that is consistently driven by BRD-NUT oncoproteins. NUT is usually fused with BRD4, and less often BRD3, highly homologous members of the bromodomain (BD)-containing BET gene family; 2,3 BRD3-and BRD4-NUT fusion proteins are collectively referred to as BRD-NUT proteins herein. Loss of BRD-NUT expression results in the terminal differentiation of NMC cells, 3 an event that is associated with proliferative arrest. BRD-NUT is tethered to chromatin through the binding of BRD's dual BDs to acetylated histones. 3 Interference with the BRD BDacetyl-histone interaction using acetyl-histone mimetics, termed as BET inhibitors, also induces the differentiation and proliferative arrest of NMC cells in cell culture and in xenograft models. 4 Based on these observations, a clinical trial of BET inhibitors has recently been opened in NMC (http://www.clinicaltrials.gov/ ct2/show/NCT01587703?term=NMC&rank=1). However, despite these encouraging clinical developments, little is known about the targets of BRD-NUT that mediate its oncogenic effects in NMC.
RESULTS AND DISCUSSION
In previous studies, we used expression profiling to characterize changes in gene expression that occur when BRD4-NUT is knocked down by siRNA in NMC cell lines, TC-797 and PER-403. 5 In an effort to identify potential transcriptional targets of BRD4-NUT, we used gene set enrichment analysis (GSEA 6 ) to compare the set of genes that are most dependent on BRD-NUT for expression in NMC cells with gene sets that are available at the Molecular Signatures Database (MSigDB, http:// www.broadinstitute.org/gsea/msigdb/). Of 3604 gene sets analyzed, the most highly correlated oncogene target signature corresponded with that of MYC ( Figure 1a ; Schuhmacher et al. 7 and Yu et al.
8
). Using the same compendium, we further compiled a collection of all represented MYC-regulated gene sets and observed significant (FDRo0.25) enrichment of 14 out of 24 gene sets. To test the possibility that MYC may be upregulated by either amplification or genomic rearrangement, we performed fluorescent in situ hybridization with MYC-flanking probes in NMC cells used in this study (TC-797) as well as a primary culture of NMC cells, 10-15 (see below). Neither amplification nor translocation of MYC was present in either NMC cell type tested (Supplementary Figure 1) . Because BRDs are hypothesized to be key regulators of MYC in other cancers, [9] [10] [11] we sought to determine the role of BRD4-NUT in driving MYC expression in NMCs.
If BRD-NUT regulates MYC expression in NMC, then we anticipated that expression of these two proteins would be tightly correlated in NMCs. As an initial test of this idea, we determined BRD-NUT and MYC expression in primary NMC using wellvalidated immunohistochemical staining methods. In all, 16 of 16 NMCs stained positively for both proteins in regions of each tumor that comprises undifferentiated basaloid cells (Figure 1b) . By contrast, staining for both proteins was absent in areas of squamous differentiation, a feature noted in all cases studied (Figure 1b) . We next performed a series of studies designed to determine whether BRD4-NUT regulates MYC expression in cultured NMC cells. By BRD4-NUT chromatin immunoprecipitation (ChIP) with an NUT-specific polyclonal antibody, we observed that BRD4-NUT binds the MYC promoter region and is displaced by the BET inhibitor, JQ1 (Figure 2a) , which prevents binding of BET BDs to acetylated histones. 4 Displacement of BRD-NUT by JQ1 was associated with decreased MYC transcription and protein levels (Figures 2b and c) . JQ1 is not specific for BRD-NUT, as it also competitively inhibits the binding of BRD2, BRD3, BRD4 and BRDT to chromatin, and NMC cells always have at least one intact BRD4 locus and express normal BRD4 as well as BRD-NUT oncoproteins; hence, the observed effects of JQ1 could stem from effects on BRD4, BRD-NUT, or both. However, knockdown of BRD4-NUT with NUT-specific siRNAs also downregulates MYC RNA and protein levels (Figures 2b and d) , suggesting that the effects of JQ1 on MYC are at least partially mediated through abrogation of BRD-NUT function.
To further test the role of the BRD BDs in NMC differentiation and MYC expression, we created an NMC cell line derivative, 797TRex, with a single Tet-regulatable genomic FRT site, and inserted a series of cDNAs encoding the tandem BDs of BRD4 (BD12) with or without point mutations in acetyl-histone binding residues 12 (BD12 N140A and/or N433A). Wild-type BD12 is predicted to compete with BRD-NUT for chromatin-binding sites, while mutated BD12 is predicted to be defective in this function. We observed that wild-type BD12 mimicked the effect of BET inhibitor by inducing NMC cell differentiation, as evidenced by upregulation of markers of squamous differentiation, such as involucrin, and changes in 797Trex cell morphology. [3] [4] [5] By contrast, point mutations of either or both BDs markedly reduced the ability of BD12 to induce differentiation, confirming that the acetyl-histone binding is required for its biological activity (Figures 2e-g ). Notably, only mutation of both BDs was able to completely prevent the induction of differentiation (Figure 2g ), indicating that the acetyl-histone binding of either BD on its own minimally retains the function of BRD-NUT. Finally, BD12 expression led to decreased MYC protein (Figure 2h ), indicating that acetyl-histone binding is required to uphold MYC expression, and supporting the idea that inhibition of MYC expression by JQ1 is through inhibition of BD12 of BRD-NUT.
MYC promotes growth and arrests the differentiation of embryonic stem cells and various neoplasms, [13] [14] [15] [16] [17] and MYC overexpression is associated with aggressive clinical behavior and worse prognosis in a number of cancers. [18] [19] [20] [21] [22] [23] [24] As such, MYC is an excellent candidate to mediate BRD-NUT oncogenic activities. To test the role of MYC in NMC cells, we knocked down MYC 6,39 Enrichment plots of genes shown previously to be upregulated by MYC 7 generated using GSEA software v2.0.9 are shown. (b) MYC is downregulated in differentiating NMC cells, in vivo. Anti-MYC and anti-NUT immunohistochemistry reveals staining of the same population of poorly differentiated tumor cells, and lack of staining in the same population of cells which have undergone squamous differentiation. NMC1 and NMC2 are BRD4-NUT NMCs excised from mediastinum and larynx, respectively. Immunohistochemical analysis for MYC and BRD4-NUT expression was performed as described. 40, 41 Photomicrographs are of the same Â 400 magnification and are from the same field for each tumor. ), for 4 h. Samples were subjected to ChIP using the SimpleChIP Chromatin IP Kit from Cell Signaling Technologies (Danvers, MA, USA). For each immunoprecipitation, 4 Â 10 7 cells were crosslinked with 1% formaldehyde for 10 min at 37 1C and nuclei were digested with micrococcal nuclease as per manufacturer instructions, with the exception that the 'high salt' wash was at 200 mM NaCl. ChIPd DNA was eluted in 200 ml. In all, 4 ml of eluted DNA was subjected to quantitative PCR (qPCR), in triplicate, using primers (Supplementary Table 1 ) designed to amplify the promoter-proximal region of MYC, and created based on distance from the transcriptional start site (TSS). qPCR was performed on a Bio-Rad iCycler in 96-well plate format with IQ SYBR Green supermix (Bio-Rad, Hercules, CA, USA). Amplification curves and Ct values were generated using MyiQ Single-Color Real-Time software (Bio-Rad) using a range of inputs (10, 0.1 and 0.01%) to generate the standard curve. Results are depicted as percent input, and are representative of one of three separate experiments with standard deviations shown. Amino acids 800-1000 of NUT were used as immunogen to make polyclonal rabbit BX.1 antibody, using methods as described 42 (Chemicon, Temecula, CA, USA). Primers used are listed in Supplementary Table 1 . (b) BRD4-NUT maintains MYC transcription. mRNA levels, as measured by quantitative reverse-transcriptase PCR (qRT-PCR), of MYC, compared with those of the reference gene Ribosomal protein L13a (RPL13a), 24 h following siRNA-mediated knockdown of BRD4-NUT, or treatment with 500 nM JQ1. All qRT-PCR experiments are representative of triplicate qRT-PCRs from one of three independent experiments. Total RNA was harvested at the indicated time points using TRizol (Invitrogen, Carlsbad, CA, USA) and the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). RNA (1 mg) was reversed transcribed into cDNA using the iScript cDNA synthesis kit (Bio-Rad). RT-qPCR was performed in triplicate on a Bio-Rad iCycler in 96 well plate format with IQ SYBR Green supermix (Bio-Rad) and 1 ml of cDNA template per reaction. Amplification curves and Ct values were generated using MyiQ Single-Color Real-Time software (Bio-Rad). Primers used are listed in Supplementary Table 1. (c) Immunoblot reveals that treatment of TC-797 NMC cells with JQ1 (500 nM) rapidly decreases MYC levels. Antibodies used were rabbit anti-MYC (1;1000, #9402, Cell Signaling Technology) and anti-GAPDH. siRNA was transfected into 2.5 Â 10 6 cells at a final concentration of 50 nM using the Nucleofector II (Lonza, Basel, Switzerland) electroporator, as described. 3 (d) BRD4-NUT is necessary for maintenance of MYC protein expression. Immunoblot of lysates from TC-797 cells 24 h following transfection with control siRNA (siCTRL, siGENOME non-targeting siRNA #4, Dharmacon, Thermo Fisher Scientific, Waltham, MA, USA) or siRNA directed at NUT (si3583, Dharmacon, sense, 5 0 -AAUUACCUUUGGAAGGAGCUAUU-3 0 , and anti-sense, 5 0 -UUUUAAUGGAAACCUUCCUCGAU-3 0 , oligonucleotides). Staining for BRD4-NUT was accomplished using AX.1 anti-NUT rabbit polyclonal antibody (1:500; Stelow et al. Immunophenotypic and morphologic (H&E) changes reveal differentiation in 797TRex-flag-BD12 cells expressing wild-type tandem BDs 1 and 2 (wtBD12), but not when point mutations of key acetyl-histone binding residues are present in either or both BDs (N140A is the key acetyl-histone binding residue of BD1, and N433A is that of BD2) of the tandem bromodomain construct (BD12), 120 h following induction. Differentiation is evidenced by morphologic (H&E) flattening and marked enlargement, and by increased expression of involucrin. (g) Immunoblot of lysates from 797TRex NMC cells 120 h following tetracycline-induced expression ('OFF' is vehicle (ethanol) treated, and 'ON' is tetracycline treated) of the dual flagtagged tandem bromodomains (BD12) of BRD4, with and without (wt) point mutations that abrogate acetyl-histone binding, demonstrates that only intact BD12 can induce differentiation, as evidenced by involucrin expression. Involucrin is a marker of squamous differentiation. Lysates 120 h after addition of tetracycline or ethanol were prepared with high-salt RIPA buffer (50 mM Tris, pH 8.0, containing 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 250 mM NaCl and 5 mM EDTA) and separated by SDS-PAGE, electrophoretically transferred onto Immobilon membranes (Millipore, Billerica, MA, USA), and stained with mouse anti-GAPDH (1:5000, 6C5; Life Technologies/Ambion, Grand Island, NY, USA), mouse anti-flag (1:1000; SigmaAldrich, St Louis, MO, USA), and mouse anti-Involucrin (1:500; Sigma-Aldrich). Staining was developed using a chemiluminescent method (SuperSignal, West Pico; Pierce, Rockford, IL, USA). The NMC cell line, TC-797, has been described. 43 A TRex derivative of the NMC cell line, TC-797, containing a single FLP recombinase site (FRT), and multiple copies of tetracycline repressor (TR) gene, to allow for the isogenic insertion of a desired tetracycline(tet)-inducible transgene, was created using the Flp-In T-Rex Core Kit and the pLenti6-TR plasmid, according to manufacturer's instructions (Invitrogen). This derivative is termed as 797TRex. Tetracycline-inducible 797TRex subclones were created according to manufacturer's instructions (Invitrogen) by co-transfection of TC-797 TRex cells (Invitrogen) with pCAGGS_FLPe and pcDNA5-Frt-TO plasmids encoding the following flag-epitope tagged polypeptides: BRD4 bromodomains 1 and 2 (BD12, residues 39-457 of BRD4); and BD12 with the point substitutions of the critical acetylhistone-binding amino acids, N140A and N433A, alone or in combination. 12 Clones were selected using Hygromycin (Invitrogen). Primers used to create these cDNAs and oligonucleotides used for site-directed mutagenesis (Stratagene/Agilent Technologies, Inc., Santa Clara, CA, USA) are provided in Supplementary Table 1 Immunophenotypic and morphologic changes 120 h following siRNA transfection in TC-797 cells reveal differentiation in those cells subjected to siRNA knockdown of MYC (siMYC, siGENOME siRNA, Human MYC (4609), Dharmacon, Thermo Fisher Scientific) compared with control siRNA (siCTRL, siGENOME non-targeting siRNA #4). All photomicrographs are Â 400 and identical scale. Formalin-fixed, paraffin-embedded cell blocks of cultured cells were prepared as described. 3, 41 Sections were stained with hematoxylin and eosin or by immunohistochemistry (IHC), which was performed on 5 mm sections. Immunohistochemical stains performed using anti-MYC (rabbit monoclonal anti-human MYC antibody, Epitomics, Inc., Burlingame, CA, USA; 1:500), and anti-involucrin (Sigma-Aldrich, St Louis, MO, USA; 1:24 000) was as described. 5 (c, d) High-throughput analysis reveals that MYC is required to block differentiation of TC-797 cells. (c) Single well from a 384-well plate reveals morphologic (increased cell area, CellMask) and immunophenotypic (increased keratin intensity, green) changes in TC-797s consistent with differentiation 72 h following transfection with siMYC or siNUT compared with siCTRL. Cells were transfected in 384-well format using 50 nM control siRNA (above), MYC siRNA (above), and NUT siRNA (above), as described. 44 Cells were stained with HCS CellMask Red Stain (Life Technologies) to measure cell area, AE1/AE3 antibody (1:4, Dako, Carpinteria, CA, USA) to measure keratin intensity, and nuclei were stained with Hoescht 33342 (4 mg/ml, Molecular Probes) to quantitate cell numbers, as described. Imaging for cell size, keratin expression and cell number was performed using the ImageXpress high-throughput microscope with MetaXpress software (Molecular Devices, Sunnyvale, CA, USA) as described. 44 Representative images taken at Â 40 magnification are shown. (d) Scatter plot of 384-well plate siRNA assay reveals differentiation of NMC cells transfected with siRNA to MYC and NUT. The differentiation phenotype is scored by an increase in cell area and keratin intensity. Each condition was performed in 384-well plate format, where 128 wells in triplicate were analyzed using MetaXpress with Multi Wavelength Cell Scoring for average cell area (pixels 2 ) per well and average keratin fluorescence pixel intensity per well. Each well is represented by a dot graphed using Vortex Software (Dotmatics, Herts, UK). (e, f) Immunophenotypic and morphologic changes 120 h following siRNA knockdown of MYC demonstrate that MYC expression is also required to block differentiation in 10-15 cells, a primary cell culture obtained from the pleural fluid of a 42-year-old man with BRD4-NUT NMC. Cells were initially grown in WIT media, 5, 45 then maintained in standard media, as described for TC-797 cells. with siRNA, and noted that this led to morphologic and immunophenotypic evidence of squamous differentiation of an NMC cell line (TC-797; Figures 3a and b) . To compare the effects of BRD-NUT knockdown and MYC knockdown quantitatively, we used high content imaging. This confirmed that MYC knockdown increased keratin expression and NMC cell size, but to a lesser degree than BRD-NUT knockdown (Figures 3c and d) . It is notable, however, that the MYC siRNA used only partially knocks down MYC protein levels in TC-797 cells, as seen at both 24 and 120 h (Figure 3a) . In fact, siRNA knockdown of BRD4-NUT leads to a greater decrease in MYC protein levels than siRNA knockdown of MYC (compare Figure 3a with Figure 2c) ; this may explain the partial differentiation phenotype upon MYC knockdown compared with BRD4-NUT knockdown. To determine whether the effects of MYC knockdown were not restricted to the TC-797 cell line, we performed siRNA knockdown of MYC in primary cultured human NMC cells from a patient who died of BRD4-NUT NMC at the time of these studies (termed as 10-15 cells), and differentiation was also observed (Figures 3e and f) . To rule out off-target effects of the siRNA, we undertook an alternative approach to MYC inhibition, and induced expression of a dominant-negative polypeptide of MYC in 797TRex cells, termed omomyc, which is a mutant version of the bHLHZip dimerization domain of MYC required for transcriptional activation of target genes. [25] [26] [27] Omomyc also potently induced differentiation (Figures  3g and h) .
Considering that our findings indicate that MYC is required for the blockade of differentiation in NMC, we next asked whether MYC is sufficient to block differentiation in the absence of BRD4-NUT. To address this, we enforced MYC expression in 797TRex cells and looked for interference with differentiation induced by knockdown of BRD-NUT. Indeed, differentiation of 797TRex cells in response to BRD-NUT knockdown was markedly attenuated in cells induced to express MYC, as evidenced by a failure of cells to flatten, enlarge, or express differentiation markers such as involucrin (Figures 4a and b) . Furthermore, rescue by MYC was accompanied by a continued high proliferation rate compared with those cells transfected with control siRNA (Figure 4c ). When compared with those cells transfected with control siRNA, the MYC-induced cells transfected with siNUT showed some degree of differentiation demonstrated by mild-tomoderate cell enlargement and a slight increase in involucrin expression (Figures 4a and b) . Thus, MYC expression was able to partially rescue knockdown of BRD4-NUT.
There are several possible reasons for why forced MYC expression cannot completely prevent differentiation in NMC cells. The most obvious possibility is that MYC may not perform all functions of BRD4-NUT necessary to block differentiation. For example, BRD4-NUT expression has been proposed to block differentiation through the repression of global histone acetylation and transcription, 5, 28 and restoration of this repressed histone acetylation using histone deacetylase inhibitors has been used as differentiation therapy in patients with NMC. 5 MYC has been reported to influence global histone modifications, but rather than repressing chromatin, MYC has been observed to open chromatin through increased global histone acetylation and/or decreased H3K27 trimethylation. [29] [30] [31] Thus, it is possible that repression of global histone acetylation induced by BRD4-NUT is the prerequisite epigenetic landscape for MYC to fully block differentiation. Moreover, both c-fos and p53 have been implicated as targets of BRD4-NUT in the pathogenesis of NMC. 28, 32 Future studies are needed to determine the relationship, if any, of MYC with the global repression of histone acetylation, and with p53 and c-fos, in NMC.
An alternative explanation for its partial rescue may be that MYC levels in the TRex system are not carefully controlled and synchronized with the cell cycle. Lack of tightly controlled MYC expression can induce apoptosis rather than promote growth. 33 In fact, cell death was noted in the 797TRex-MYC cells exposed to prolonged induction of MYC expression (data not shown).
MYC serves a dichotomous role in differentiation. While in some contexts it is thought to block differentiation, in others, such as in skin homeostasis, it is thought to initiate differentiation. Our above finding (Figure 1b ) that MYC expression is absent in terminally differentiating NMC cells is not necessarily at odds with its role in the epidermis. [34] [35] [36] In fact, we found that MYC was expressed only in the basal and supra-basal cells of normal squamous epithelium present in excision specimens, and was undetectable in more differentiated keratinocytes (Supplementary Figure 2) . The findings support a model whereby transient MYC expression is necessary for the initiation of squamous differentiation, but not for ongoing terminal differentiation. Thus, in NMC, MYC expression may simultaneously poise the cells for differentiation, while also blocking progression of differentiation. Support for this model has been reported where ongoing expression of MYC leads to squamous hyperplasia, and likewise, transient loss of MYC leads to exit of proliferating keratinocytes from the cell cycle. 27, 37, 38 Together, our findings demonstrate that BRD4-NUT blocks differentiation by maintaining the expression of MYC. Importantly, however, the function of BRD4-NUT, which is structurally different from BRD4, is unknown. Despite its presence at the MYC promoter region, BRD4-NUT should not be assumed to directly regulate transcription of MYC as is hypothesized for BRD4. In fact, reported findings suggest that BRD4-NUT is not associated with transcription. 28, 32 It remains unclear whether BRD4-NUT acts directly or indirectly, as either a repressor or activator, in its role to increase MYC levels.
The presence of a fusion oncogene in this subtype of 'NUTpositive' squamous cell carcinoma offers a rare opportunity to probe what may reveal a mechanism common to other epithelial cancers, and the critical role of MYC is early evidence to support this notion. Mouse models of MYC inhibition using omomyc have demonstrated much less toxic than anticipated, thus targeting of MYC may lead to therapies for NMC and more common tumors.
